Meeting of the Advisory Committee on Immunization Practices, 42656 [2018-18184]

Download as PDF 42656 Federal Register / Vol. 83, No. 164 / Thursday, August 23, 2018 / Notices would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)— RFA–CE19–001, Injury Control Research Centers. Dates: October 30, 2018 and November 2, 2018 Time: 8:30 a.m.–5:00 p.m., EDT Place: The Georgian Terrace, 659 Peachtree St. NE, Atlanta, GA, 30308 Agenda: To review and evaluate grant applications. For Further Information Contact: Mikel L. Walters, M.A., Ph.D., Scientific Review Official, NCIPC, CDC, 4770 Buford Highway NE, Mailstop F–63, Atlanta, Georgia 30341, Telephone: (404) 639–0913; Email: mwalters@ cdc.gov. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Sherri Berger, Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2018–18188 Filed 8–22–18; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Meeting of the Advisory Committee on Immunization Practices Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice of meeting. AGENCY: In accordance with the Federal Advisory Committee Act, the CDC announces the following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the public, limited only by room seating. The meeting room accommodates 400. Time will be available for public comment. DATES: The meeting will be held on October 24, 2018, 8:30 a.m. to 5:15 p.m., EDT, and October 25, 2018, 8:30 a.m. to 4:00 p.m. EDT. The public is welcome to submit written comments in advance of the meeting. Comments should be submitted in writing by email to the contact person listed in FOR FURTHER daltland on DSKBBV9HB2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 19:43 Aug 22, 2018 Jkt 244001 INFORMATION CONTACT. The deadline for receipt is October 15, 2018. ADDRESSES: CDC, 1600 Clifton Road NE, Tom Harkin Global Communications Center, Kent ‘Oz’ Nelson Auditorium, Atlanta, GA 30329–4027. The meeting will be webcast live via the World Wide Web; for instructions and more information on ACIP please visit the ACIP website: https:// www.cdc.gov/vaccines/acip/. FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, ACIP Committee Management Specialist, CDC, NCIRD, telephone 404–639–8836, email ACIP@ cdc.gov. SUPPLEMENTARY INFORMATION: Purpose: The committee is charged with advising the Director, CDC, on the use of immunizing agents. In addition, under 42 U.S.C. 1396s, the committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding dosing interval, dosage, and contraindications to administration of vaccines. Further, under provisions of the Affordable Care Act, section 2713 of the Public Health Service Act, immunization recommendations of the ACIP that have been approved by the Director of the Centers for Disease Control and Prevention and appear on CDC immunization schedules must be covered by applicable health plans. Matters to Be Considered: The agenda will include discussions on child/ adolescent immunization schedule, adult immunization schedule, human papillomavirus vaccines, pneumococcal vaccines, Japanese encephalitis vaccines, zoster vaccine, Influenza vaccines, general recommendations, anthrax vaccine, hepatitis A vaccine, Pertussis vaccine, and meningococcal vaccines. A recommendation vote is scheduled for child/adolescent immunization schedule and adult immunization schedule. Agenda items are subject to change as priorities dictate. For more information on the meeting agenda visit https:// www.cdc.gov/vaccines/acip/meetings/ meetings-info.html. Public Comment: Written comments must include full name, address, organizational affiliation, email address of the speaker, topic being addressed and specific comments. Written comments must not exceed one singlespaced typed page with 1-inch margins containing all items above. Only those written comments received 10 business days in advance of the meeting will be included in the official record of the PO 00000 Frm 00021 Fmt 4703 Sfmt 4703 meeting. Public comments made in attendance must be no longer than 3 minutes and the person giving comments must attend the public comment session at the start time listed on the agenda. Time for public comments may start before the time indicated on the agenda. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Sherri Berger, Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2018–18184 Filed 8–22–18; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [60Day–18–18ATK; Docket No.CDC–2018– 0075] Proposed Data Collection Submitted for Public Comment and Recommendations Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice with comment period. AGENCY: The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other Federal agencies the opportunity to comment on a proposed and/or continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled Understanding multi-sectoral collaboration for strengthening public health capacities in Ethiopia. The goal of this study is to explore multi-sectoral collaboration in Ethiopia, in the context of strengthening public health capacities under the Global Health Security Agenda. SUMMARY: CDC must receive written comments on or before October 22, 2018. DATES: You may submit comments, identified by Docket No. CDC–2018– 0075 by any of the following methods: ADDRESSES: E:\FR\FM\23AUN1.SGM 23AUN1

Agencies

[Federal Register Volume 83, Number 164 (Thursday, August 23, 2018)]
[Notices]
[Page 42656]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-18184]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Meeting of the Advisory Committee on Immunization Practices

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: In accordance with the Federal Advisory Committee Act, the CDC 
announces the following meeting of the Advisory Committee on 
Immunization Practices (ACIP). This meeting is open to the public, 
limited only by room seating. The meeting room accommodates 400. Time 
will be available for public comment.

DATES: The meeting will be held on October 24, 2018, 8:30 a.m. to 5:15 
p.m., EDT, and October 25, 2018, 8:30 a.m. to 4:00 p.m. EDT.
    The public is welcome to submit written comments in advance of the 
meeting. Comments should be submitted in writing by email to the 
contact person listed in FOR FURTHER INFORMATION CONTACT. The deadline 
for receipt is October 15, 2018.

ADDRESSES: CDC, 1600 Clifton Road NE, Tom Harkin Global Communications 
Center, Kent `Oz' Nelson Auditorium, Atlanta, GA 30329-4027.
    The meeting will be webcast live via the World Wide Web; for 
instructions and more information on ACIP please visit the ACIP 
website: https://www.cdc.gov/vaccines/acip/.

FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, ACIP Committee 
Management Specialist, CDC, NCIRD, telephone 404-639-8836, email 
[email protected].

SUPPLEMENTARY INFORMATION:
    Purpose: The committee is charged with advising the Director, CDC, 
on the use of immunizing agents. In addition, under 42 U.S.C. 1396s, 
the committee is mandated to establish and periodically review and, as 
appropriate, revise the list of vaccines for administration to vaccine-
eligible children through the Vaccines for Children (VFC) program, 
along with schedules regarding dosing interval, dosage, and 
contraindications to administration of vaccines. Further, under 
provisions of the Affordable Care Act, section 2713 of the Public 
Health Service Act, immunization recommendations of the ACIP that have 
been approved by the Director of the Centers for Disease Control and 
Prevention and appear on CDC immunization schedules must be covered by 
applicable health plans.
    Matters to Be Considered: The agenda will include discussions on 
child/adolescent immunization schedule, adult immunization schedule, 
human papillomavirus vaccines, pneumococcal vaccines, Japanese 
encephalitis vaccines, zoster vaccine, Influenza vaccines, general 
recommendations, anthrax vaccine, hepatitis A vaccine, Pertussis 
vaccine, and meningococcal vaccines. A recommendation vote is scheduled 
for child/adolescent immunization schedule and adult immunization 
schedule. Agenda items are subject to change as priorities dictate. For 
more information on the meeting agenda visit https://www.cdc.gov/vaccines/acip/meetings/meetings-info.html.
    Public Comment: Written comments must include full name, address, 
organizational affiliation, email address of the speaker, topic being 
addressed and specific comments. Written comments must not exceed one 
single-spaced typed page with 1-inch margins containing all items 
above. Only those written comments received 10 business days in advance 
of the meeting will be included in the official record of the meeting. 
Public comments made in attendance must be no longer than 3 minutes and 
the person giving comments must attend the public comment session at 
the start time listed on the agenda. Time for public comments may start 
before the time indicated on the agenda. The Director, Management 
Analysis and Services Office, has been delegated the authority to sign 
Federal Register notices pertaining to announcements of meetings and 
other committee management activities, for both the Centers for Disease 
Control and Prevention and the Agency for Toxic Substances and Disease 
Registry.

Sherri Berger,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2018-18184 Filed 8-22-18; 8:45 am]
 BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.